Suppliers and packagers for generic pharmaceutical drug: NAPROXEN

NAPROXEN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Atnahs Pharma Us	NAPROSYN	naproxen	SUSPENSION;ORAL	018965	NDA AUTHORIZED GENERIC	Acella Pharmaceuticals, LLC	42192-619-16	473 mL in 1 BOTTLE (42192-619-16)	2020-11-12
Amneal	NAPROXEN	naproxen	SUSPENSION;ORAL	212705	ANDA	Amneal Pharmaceuticals NY LLC	69238-1730-2	473 mL in 1 BOTTLE (69238-1730-2)	2020-08-03
Aurobindo Pharma	NAPROXEN	naproxen	SUSPENSION;ORAL	216504	ANDA	Aurobindo Pharma Limited	59651-528-47	1 BOTTLE in 1 CARTON (59651-528-47) / 473 mL in 1 BOTTLE	2025-10-03
Hetero Labs Ltd Iii	NAPROXEN	naproxen	SUSPENSION;ORAL	215776	ANDA	Camber Pharmaceuticals, Inc.	31722-682-05	500 mL in 1 BOTTLE (31722-682-05)	2022-06-07
Hikma	NAPROXEN	naproxen	SUSPENSION;ORAL	074190	ANDA	Hikma Pharmaceuticals USA Inc.	0054-3630-63	500 mL in 1 BOTTLE, PLASTIC (0054-3630-63)	2021-02-24
Novitium Pharma	NAPROXEN	naproxen	SUSPENSION;ORAL	211910	ANDA	ANI Pharmaceuticals, Inc.	70954-151-10	500 mL in 1 BOTTLE (70954-151-10)	2021-03-12

Naproxen Supply Chain: Key Manufacturers and Regulatory Landscape

Last updated: February 19, 2026

This analysis details the primary suppliers of naproxen active pharmaceutical ingredient (API) and the regulatory considerations impacting its production. Key manufacturers, patent statuses, and production capacities are identified to inform R&D and investment decisions.

Who are the Major Naproxen API Manufacturers?

The global supply of naproxen API is concentrated among a limited number of manufacturers, primarily located in Asia. These companies possess significant production capacities and have established supply chains to serve major pharmaceutical markets.

Leading Naproxen API Suppliers:

• Haidian Pharm (China): A significant producer with established manufacturing capabilities.
• Jiangsu Hansoh Pharmaceutical (China): A key player in the Chinese pharmaceutical API market.
• Zhejiang NHU Company (China): Another prominent Chinese manufacturer with a broad API portfolio.
• Anistal Pharmaceutical (India): An Indian company contributing to the global supply.
• Divi’s Laboratories (India): A major pharmaceutical intermediates and API manufacturer with substantial capacity.

These manufacturers are subject to stringent quality control standards and regulatory oversight, particularly from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Production sites are regularly inspected to ensure compliance with Good Manufacturing Practices (GMP).

What is the Patent Landscape for Naproxen?

Naproxen is a well-established nonsteroidal anti-inflammatory drug (NSAID) whose primary composition-of-matter patents have long expired. This has led to a highly genericized market for both the API and finished dosage forms.

Key Patent Information:

• Original Patent Expiration: The foundational patents for naproxen, originally developed by Syntex Corporation (later acquired by Roche), expired decades ago. This allowed for the widespread development and manufacturing of generic versions.
• Current Patent Activity: While the core compound is off-patent, recent patent filings typically focus on:
  • New polymorphs: Novel crystalline forms of naproxen that may offer improved stability, dissolution, or manufacturing characteristics.
  • Manufacturing processes: Improved synthetic routes or purification methods that enhance efficiency, reduce by-products, or lower costs.
  • Formulations: Novel drug delivery systems, such as extended-release formulations, combination therapies, or topical applications.

Companies seeking to enter or expand within the naproxen market must conduct thorough freedom-to-operate (FTO) analyses to ensure they do not infringe on any existing process or formulation patents. The lack of composition-of-matter patent protection means competition is primarily driven by cost, quality, and supply reliability.

How is Naproxen API Production Regulated?

The production and sale of naproxen API are strictly regulated by national and international health authorities to ensure patient safety and product efficacy. Key regulatory bodies and their requirements include:

Major Regulatory Bodies and Requirements:

• U.S. Food and Drug Administration (FDA):
  • Current Good Manufacturing Practices (cGMP): Manufacturers must adhere to 21 CFR Part 210 and 211, which outline requirements for facilities, equipment, processes, and quality control.
  • Drug Master Files (DMFs): API manufacturers typically file Type II DMFs with the FDA. These confidential documents contain detailed information about the API's manufacturing process, facility, and quality controls. Pharmaceutical companies reference these DMFs in their Abbreviated New Drug Applications (ANDAs) for generic drugs.
  • Facility Inspections: FDA conducts routine inspections of API manufacturing sites globally.
• European Medicines Agency (EMA):
  • EudraGMDP Database: API manufacturers need to be listed in the EudraGMDP database, indicating compliance with GMP standards as verified by inspections from European national competent authorities.
  • Certificates of Suitability (CEP): Manufacturers can obtain a CEP from the European Directorate for the Quality of Medicines & HealthCare (EDQM), which demonstrates compliance with the European Pharmacopoeia and GMP.
• Other National Agencies: Similar regulatory frameworks exist in countries like Japan (PMDA), Canada (Health Canada), and Australia (TGA).

Quality Standards:

• Pharmacopoeial Compliance: Naproxen API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define purity, assay, impurity limits, and other critical quality attributes.
• Impurity Profiling: Manufacturers must rigorously identify, quantify, and control process-related impurities and degradation products. ICH guidelines (e.g., Q3A for new drug substances, Q3B for new drug products) provide frameworks for impurity assessment.

What are the Production Capacities and Trends in Naproxen API Manufacturing?

The production capacity for naproxen API is substantial, driven by its widespread use as a generic medication. While specific, up-to-date figures are often proprietary, market analysis indicates a global capacity sufficient to meet demand.

Key Trends:

• Cost Optimization: With expired patents, manufacturers focus on cost-effective production. This often involves optimizing synthetic routes, improving yields, and leveraging economies of scale.
• Supply Chain Resilience: Pharmaceutical companies are increasingly scrutinizing their API supply chains for vulnerabilities. This may lead to diversification of suppliers and greater emphasis on manufacturers with robust quality systems and reliable track records.
• Geographic Concentration: The majority of API production remains concentrated in China and India due to lower manufacturing costs and established chemical synthesis infrastructure.
• Quality Assurance Emphasis: Regulatory scrutiny is increasing globally. Manufacturers demonstrating superior quality control and regulatory compliance have a competitive advantage.

Market Dynamics:

• Generic Competition: The naproxen market is highly competitive, with numerous generic manufacturers offering both API and finished products.
• Price Sensitivity: Pricing is a critical factor for market share, directly influenced by API manufacturing costs.
• Demand Stability: As a widely used over-the-counter (OTC) and prescription drug, naproxen demand is generally stable, though subject to seasonal variations and competitive pressures from other NSAIDs.

What are the Risks and Opportunities for Naproxen API Supply?

The naproxen API market presents both challenges and opportunities for pharmaceutical companies and investors.

Risks:

• Supply Chain Disruptions: Geopolitical events, natural disasters, or regulatory actions in major producing countries (China, India) can disrupt supply.
• Quality Failures: Instances of API contamination or failure to meet pharmacopoeial standards can lead to product recalls, regulatory sanctions, and reputational damage.
• Price Volatility: Fluctuations in raw material costs, energy prices, or currency exchange rates can impact API pricing.
• Increasing Regulatory Burden: Evolving GMP requirements and stricter impurity controls necessitate ongoing investment in compliance.

Opportunities:

• Process Innovation: Development of novel, more efficient, or environmentally friendly synthetic pathways could offer a competitive edge and cost savings.
• Supply Chain Diversification: Companies that can secure reliable supply from multiple, geographically diverse sources may mitigate risks.
• High-Quality, Compliant Manufacturers: Investment in or partnerships with API manufacturers demonstrating exceptional quality control and regulatory adherence can create a strong market position.
• Emerging Markets: Growth in pharmaceutical consumption in emerging economies can create new demand channels.

Key Takeaways

• Naproxen API manufacturing is dominated by producers in China and India, characterized by high volume and cost-driven competition.
• The foundational patents for naproxen have expired, leading to a mature generic market. Current patent activity focuses on process improvements and novel formulations.
• Regulatory compliance with GMP standards from agencies like the FDA and EMA is paramount. API manufacturers must maintain Drug Master Files (DMFs) and undergo regular inspections.
• Key trends include cost optimization, supply chain resilience, and an increasing emphasis on quality assurance.
• Risks include supply chain disruptions and quality failures, while opportunities lie in process innovation and securing diversified, high-quality supply chains.

Frequently Asked Questions

What are the primary raw materials used in naproxen synthesis?

The synthesis of naproxen typically begins with precursors such as 2-methoxynaphthalene. The specific synthetic route employed by a manufacturer determines the exact sequence and intermediate materials used, but common themes involve alkylation, carbonylation, and chiral resolution steps.

How does the regulatory environment for API manufacturing impact naproxen pricing?

Strict GMP compliance, extensive documentation, and regular inspections add to manufacturing costs. Companies that successfully navigate these regulations and maintain a strong compliance record can achieve greater market access and pricing stability, while non-compliant manufacturers face significant financial and operational risks.

What is the typical shelf life of naproxen API?

The shelf life of naproxen API is generally determined by stability studies conducted by the manufacturer and specified in the API's Certificate of Analysis. This typically ranges from two to five years when stored under recommended conditions, provided the API is manufactured and handled according to GMP.

Are there any specific impurity concerns associated with naproxen production?

As with most chemical syntheses, naproxen production can generate process-related impurities, including residual solvents, unreacted starting materials, and by-products. Degradation products can also form over time. Manufacturers must control these impurities to meet pharmacopoeial limits and ensure patient safety.

What is the impact of the U.S. Drug Master File (DMF) system on naproxen API sourcing?

The DMF system allows API manufacturers to submit proprietary information about their manufacturing process directly to the FDA. Pharmaceutical companies seeking to market a generic naproxen product can then reference this DMF in their ANDA, streamlining the regulatory review process without directly accessing the manufacturer's confidential data.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA website] (Note: Specific URL would depend on the exact page, e.g., https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp)

[2] European Medicines Agency. (n.d.). EudraGMDP database. Retrieved from [EMA website] (Note: Specific URL would depend on the exact page, e.g., https://www.ema.europa.eu/en/about-ema/contact-us/eudragmp-database)

[3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM website] (Note: Specific URL would depend on the exact page, e.g., https://www.edqm.eu/en/certificate-suitability-cep)

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website] (Note: Specific URL would depend on the exact guideline, e.g., https://www.ich.org/page/quality-guidelines)